1. Scrip
  2. >>Business

Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone

Bypasses Union Objections To Downsizing

 
• By Andrew McConaghie

Hudson finds solution for legacy sites which have dogged predecessors.

Sanofi_France
Shedding its older manufacturing sites is the latest step in Sanofi's rejuventation

Sanofi’s new CEO Paul Hudson has come up with a neat solution to what to do with a string of six outdated manufacturing sites across Europe.

The company is to spin-out the sites into a standalone active pharmaceutical ingredient (API) manufacturing company, which

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.